REFERENCES
2. Luft R, Ikkos D, Palmiere G, Ernster L, Afzelius B. A case of severe hypermetabolism of nonthryoid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962;41:1776-804.
3. Nass MMK, Nass S. Intramitochondrial fibers with DNA characteristics: I. Fixations and electron stamping reactions. J Cell Biol 1963;19:593-611.
4. Nass S, Nass MMK. Intramitochondrial fibers with DNA characteristics: II. Enzymatic and other hydrolytic reactions. J Cell Biol 1963;19:613-92.
5. Anderson S, Bankier AT, Barrell BG, de Bruijn HM, Coulson AR, et al. Sequence and organization of the human mitochondrial genome. Nature 1981;290:457-65.
6. Holt IJ, Harding AE, Morgan Hughes JA. A new mitochondrial disease associated with DNA in patients with mitochondrial myopathies. Nature 1988;331:717-19.
7. Wallace CC, Sigh G, Lott MT, Hodge JA, Shurr TG, et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988;242:1427-30.
8. Endo H, Hasegawa K, Narisawa K, Tada K, Kagawa Y, et al. Defective gene in lactic acidosis: abnormal pyruvate dehydrogenase E1 a-subunit caused by a frameshift. Am J Hum Genet 1989;44:358-64.
9. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995;11:144-49.
10. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 2015;77:753-59.
11. Skladal D, Halliday J, Thorborn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003;126:1905-12.
12. Frazier AE, Thorburn DR, Compton AG. Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. J Biol Chem 2019;294:5386-95.
13. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatr 1951;14:216-21.
14. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, et al. Diagnostic criteria for respiratory chain disorder in adults and children. Neurology 2002;59:1406-11.
15. Spiro AJ, Moore CL, Prineas JW, Stasberg PM, Rapin I. A cytochrome-related inherited disorder of the nervous system and muscle. Arch Neurol 1970;23:103-12.
16. Willems JL, Monnens L, Trijbels J, Veerkamp JH, Meyer A, et al. Leigh’s encephalomyelopathy in a patient with cytochrome c oxidase deficiency in muscle tissue. Pediatrics 1977;60:850-7.
17. Shapira Y, Harel S, Russell A. Mitochondrial encephalopmyopathies: A group of neuromuscular disorders with defects in oxidative metabolism. Israel J of Med Sci 1977;13:161-4.
18. Rodenburg RJ, Schoonderwoerd GC, Tiranti V, Taylor RW, Rotig A, et al. A multi-center comparison of diagnostic methods for the biochemical evaluation of suspected mitochondrial disorders. Mitochondrion 2013;13:36-43.
19. Chen X, Thorburn DR, Wong LJ, Vladutiu G, Haas RH, et al. Quality improvement of mitochondrial respiratory chain complex enzyme assays using Caenorhabditis Elegans. Genet Med 2011;13:794-9.
20. Witters P, Saada A, Honzik T, Tesarova M, Kleinle S, et al. Revisiting mitochondrial diagnostic criteria in the new era of genomics. Genet Med 2018;20:444-51.
21. Bai RK, Wong LJ. Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. Clin Chem 2004;50:996-1001.
22. Tang S, Wang J, Zhang VW, Li FY, Landsverk M, et al. Transition to next generation analysis of the whole mitochondrial genome: a summary of molecular defects. Hum Mut 2013;34:882-93.
24. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Ann Rev Genomics Hum Genet 2010;11:25-44.
25. Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res 2016;44:D1251-7.
26. DaRe JT, Vasta V, Penn J, Tran NTB, Hahn SH. Targeted exome sequencing for mitochondrial disorders reveals high genetic heterogeneity. BMC Med Genet 2013;11:118.
27. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, et al. Practice patterns of mitochondrial disease physicians in North America. Part I: diagnostic and clinical challenges. Mitochondrion 2014;14:26-33.
28. Thompson K, Collier JJ, Glasgow RIC, Robertson FM, Pyle A, et al. Recent advances in understanding the molecular genetic basis of mitochondrial disease. J Inherit Metab Dis 2019;43:36-50.
29. Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, et al. Deleterious-and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 2012;91:1022-31.
30. Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource. Am J Hum Genet 2017;100:895-906.
31. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, et al. ClinGen-The clinical genome resource. N Engl J Med 2015;372:2235-42.
32. Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
33. Saneto RP, Naviaux RK. Polymerase gamma disease through the ages. Dev Disabil Res Rev 2010;16:163-74.
34. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, et al. POLG DNA testing as an emerging standard of care before institution of valproic acid therapy for pediatric seizure disorders. Seizure 2010;19:140-6.
35. Yamanaka H, Gatanaaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, et al. Novel mutation of human DNA polymerase g associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 2007;195:1419-25.
36. Cai W, Fu Q, Zhou X, Qu J, Tong Y, et al. Mitochondrial variants may influence the phenotypic manifestation of Leber’s hereditary optic neuropathy-associated ND4 G11778A mutation. J Genet Genomics 2008;35:649-55.
37. Mitchell AL, Elison JL, Howell N, Taylor RW, Turnbull DM. Sequence variation in mitochondrial complex I genes; mutation or polymorphism. J Med Genet 2006;43:175-9.
38. Shoffner JM, Lott MT, Lezza AMS, Seibel P, Ballinger SW, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(lys) mutation. Cell 1990;61:931-7.
39. Boczonadi V, Jennings MJ, Horvath R. The role of tRNA synthetases in neurological and neuromuscular disorders. FEBS Lett 2018;592:703-17.
40. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013;9:429-44.
41. Archer SL. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N Engl J Med 2013;369:2236-51.
42. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011;147:893-906.
43. Varadi A, Johnson-Cadwall LI, Cirulli V, Yoon Y, Allan VJ, et al. Cytoplasmic dynein regulates the subcellular distribution of mitochondria by controlling the recruitment of fission factor dynamin-related protein-I. J Cell Sci 2004;117:4389-400.
44. Duchen MR. Mitochondria and calcium: from cell signaling to cell death. J Physiol 2000;529:57-68.
45. de Brito OM, Scorrano L. An intimate liaison: spatial organization of the endoplasmic reticulum-mitochondria relationship. EMBO J 2010;29:2715-23.
46. Glancy B, Balaban RS. Role of mitochondrial Ca2+ in the regulation of cellular energetics. Biochemistry 2012;51:2959-73.
47. Guda P, Guda C, Subramaniam S. Reconstruction of pathways associated with amino acid metabolism in human mitochondria. Genome Proteomics Bioinformatics 2007;5:166-76.
48. Koopman WJH, Nijtmans LGJ, Dieteren CEJ, Roestenberg P, Valsecchi F, et al. Mammalian mitochondrial complex I: Biogenesis, regulation, and reactive oxygen species generation. Antioxidant Redox Signal 2010;12:1431-70.
49. Stehling O, Wilbrecht C, Lill R. Mitochondrial iron-sulfur protein biogenesis and human disease. Biochimie 2014;100:61-77.
51. Kukat C, Wurm CA, Spahr H, Falkenberg M, Larsson MG, et al. Super-resolution microscopy reveals that mitochondria nucleoids have a uniform size and frequency contain a single copy of mtDNA. Proc Natl Acad Sci USA 2011;108:13534-39.
52. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, et al. Mitochondrial diseases. Nat Rev Dis Primers 2016;2:16080.
53. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet 2015;16:530-42.
54. Grady JP, Pickett SJ, Ng YS, Alston CI, Blakely EL, et al. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO Mol Med 2018;10:e8262.
56. Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. The genetics and pathology of mitochondrial disease. J Pathol 2017;241:236-50.
57. Lott MT, Leipzi JN, Derbeneva JN, Xie O, Chalkia HM, et al. MtDNA variation and analysis using Mitomap and Mitomaster. Curr Protoc Bioiformatics 2013;44:1.23.1-26.
58. Mayr JA, Haack TB, Freisinger P, Karall D, Makowski C, et al. Spectrum of combined respiratory chain defects. J Inherit Metab Dis 2015;38:629-40.
59. Friederich MW, Erdogan AJ, Coughlin CR 2nd, Elos MT, Jiang H, et al. Mutations in the accessory subunit NDUFB10 result in isolated complex I deficiency and illustrate the critical role of intermembrane space import for complex I holoenzyme assembly. Hum Mol Genet 2017;26:702-16.
60. Sanchez-Caballero L, Guerrero-Castillo S, Nijtmans L. Unraveling the complexity of mitochondrial complex I assembly: a dynamic process. Biochim Biophys Acta 2016;1857:980-90.
61. Stroud DA, Surgenor EE, Formosa LE, Reljic B, Frazier AE, et al. Accessory subunits are integral for assembly and function of human mitochondrial complex I. Nature 2016;538:123-26.
62. Friederich MW, Perez FA, Knight KM, Van Hove RA, Yang SP, et al. Pathogenic variants in NUBPL result in failure to assemble the matrix arm of complex I and cause a complex leukoencephalopathy with thalamic involvement. Mol Genet Metab 2020;129:236-42.
63. Fassone E, Rahman S. Complex I deficiency: clinical features biochemistry and molecular genetics. J Med Genet 2012;49:578-90.
64. Lake NJ, Cmpton AG, Rahman S, Thorburn DR. Leigh syndrome: one disorder, more than 75 monogenic causes. Ann Neurol 2016;79:190-203.
65. Pagniez-Mammeri H, Loublier S, Legrand A, Fenit P, Rustin P, et al. Mitochondrial complex I deficiency of nuclear origin I: structural genes. Mol Genet Metab 2012;105:163-72.
66. Ghezzi D, Goffrine P, Uziel G, Horvath R, Klopstock T, et al. SDHAF1 encoding a LYHR complex-II specific assembly factor is mutated in SDH-defective infantile leukoencephalopathy. Nature Genet 2009:654-6.
67. Renkema GH, Wortmann SB, Smeets RJ, Venselaar H, Antoine Mu, et al. SDHA mutations casing a multisystem mitochondrial disease: novel mutations and genetic overlap with hereditary tumors. Eur J Hum Genet 2015;23:202-9.
68. Alston CL, Davison JE, Meloni F, van der Westhuizen FH, He L, et al. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet 2012;49:569-77.
69. Jackson CB, Nuoffer JM, Han D, Prokisch H, Haberberger B, et al. Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. J Med Genet 2014;51:170-5.
70. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 2009;16:391-400.
71. Fernandez-Vizarra E, Zeviani M. Nuclear gene mutations as the cause of mitochondrial complex III deficiency. Front Genet 2015;6:134.
72. Visappa I, Fellman V, Vesa J, Dasvarma A, Hutton JL, et al. GRACILE syndrome, a lethal metabolic disorder with iron overload is caused by a point mutation in BCSIL. Am J Hum Genet 2002;71:863-76.
73. Olahova M, Berti CC, Collier JJ, Alston C, Jameson E, et al. Molecular genetic investigations identify new clinical phenotypes associated with BCS1L-realted mitochondrial disease. Hum Mol Genet 2019;28:3766-76.
74. Zong S, Wu M, Gu J, Liu T, Gua R, et al. Structure of the intact 14-subunit human cytochrome c oxidase. Cell Res 2018;28:1026-34.
75. Rak M, Benit P, Chretern D, Bouchereau, Schiff M, et al. Mitochondrial cytochrome c oxidase deficiency. Clin Sci 2016;130:393-407.
76. Wedatilake Y, Brown RM, McFarland R, Yaplito-Lee J, Morris AAM, et al. SURF1 deficiency: A multi-center natural history study. Orphnet J Rare Dis 2013;8:96.
77. Hallmann K, Kudin AP, Zsurka G, Kornblum C, Reimann JU, et al. Loss of the smallest subunit of cytochrome c oxidase, COX8A, causes Leigh-like syndrome and epilepsy. Brain 2016;139:338-45.
78. Tamiya G, Makino S, Hayshi M, Abe A, Numakura C, et al. A mutation of COX64A1 causes recessive axonal or mixed form of Charcot-Marie-Tooth disease. Am J Hum Genet 2014;95:294-300.
79. Signes A, Cerutti R, Dickson AS, Beninca C, Hinchy EC, et al. APOTP1/COA8 assembly and is oppositely regulated by UPS and ROS. EMBO Mol Med 2019;11:e9582.
80. Melchionda L, Haack TB, Hardy S, Abbink TEM, Fernandez-Vizarra E, et al. Mutations in
81. Jonckheere AI, Smeitink JAM, Rodenburg RJT. Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis 2011;35:211-25.
82. Akagi M, Inui K, Tsukamoto H, Sakai N, Muramatsu T, et al. A point mutation of mitochondrial ATPase 6 gene in Leigh syndrome. Neuromuscul Disord 2002;12:53-5.
83. Holt TJ, Harding AE, Petty RKH, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990;46:428-33.
84. Stendel C., Neuhofer C, Floride E, Yuqing S, Ganetzky RD, et al. Delineating MT-ATP6-associated disease: From isolated neuropathy to early onset neurodegeneration. Neurol Genet 2020;6:e393.
85. Mayr JA, Havlickova V, Zimmermann F, Magler I, Kaplanova V, et al. Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 e subunit. Hum Mol Genet 2010;19:3430-9.
86. Spiegel R, Khayat M, Shalev SA., Horovitz Y, Mandel H, et al. TMEM70 mutations are a common cause of nuclear encoded ATP synthase assembly defect: further delineation of a new syndrome. J Med Genet 2011;48:177-82.
87. Siegmund SE, Grassucci R, Carter SD, Barca E, Farino ZJ, et al. Three-dimensional analysis of mitochondrial crista ultrastructure in a patient with Leigh syndrome by in situ cryoelectron tomography. iScience 2018;6:83-91.
88. Barca E, Ganetzky RD, Potluri P, Juanola-Falgarona M, Gai X, et al. USMG5 Ashkenazi Jewish founder mutations impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 2018;27:3305-12.
89. Sofou K, De Coo IFM, Isohanni P, Ostergaard E, Naess K, et al. A multicenter study on Leigh syndrome: disease course and predictions on survival. Orphan J Rare Dis 2014;9:52.
90. Rahman S, Blok RB, Dahl HHM, Danks DM, Kirby DM, et al. Leigh syndrome. Clinical features and biochemical and DNA abnormalities. Ann Neurol 1996;39:343-51.
91. Ruhoy IS, Saneto RP. The genetics of Leigh syndrome and its implication for clinical practice and risk management. The App Clin Genet 2014;7:221-34.
92. McKelvie P, Infeld B, Marotta R, Chin J, Thorburn D, et al. Late-adult onset Leigh syndrome. J Clin Neurosci 2012;19:195-202.
93. Saneto RP, Friedman SD, Shaw DWW. Neuroimaging of mitochondrial disease. Mitochondrion 2008;8:396-413.
94. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99.
95. Trevisson E, DiMauro S, Vavas P, Salvati L. Coenzyme Q deficiency in muscle. Curr Opinion in Neurol 2011;24:440-56.
96. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ10) deficiency. J Inherit Metab Dis 2015;38:145-56.
97. Babbitt SE, Sutherland MC, San Francisco B, Mendez DL, Kranz RG. Mitochondrial cytochrome c biogenesis: no longer an enigma. Trends Biochem Sci 2015;40:446-55.
98. Wimplinger I, Morleo M, Rosenberger G, Iaconis D, Orth U, et al. Mutations of the mitochondrial holocytochrome c-type synthase in X-linked dominant microphthalmia with linear skin defects syndrome. Am J Hum Genet 2006;79:878-89.
99. Uchiyama Y, Yanagisawa K, Dunishima S, Shina M, Ogawa Y, et al. A novel CYHCS mutation in the a-helix of the CYCS C-terminal domain causes non-syndromic thrombocytopenia. Clin Genet 2018;94:548-53.
100. Ow YP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol 2008;9:532-42.
101. Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, et al. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 1989;144:346-9.
102. Sadikovic B, Wang J, El-Hattab A, Landsverk M, Douglas G, et al. Sequence homology at the breakpoint and clinical phenotype of mitochondrial DNA deletion syndromes. PLoS One 2010;5:e15687.
103. Chen X, Prosser R, Simonetti S, Sadlock J, Jagiello G, et al. Rearranged mitochondrial genomes are present in human oocytes. Am J Hum Genet 1995;57:239-47.
104. Hayashi JI, Ohta S, Kikuchi A, Takemitsu M, Goto Y, et al. Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. Proc Natl Acad Sci USA 1991;88:10614-8.
105. Gustafson MA, McCormick EM, Perera L, Longley MJ, Bai R, et al. Mitochondrial single-stranded DNA binding protein novel de novo SSBP1 mutation in a child with single large-scale mtDNA deletion (SLSMD) clinically manifesting as Pearson, Kearns-Sayre, and Leigh syndromes. PLoS One 2019;14:e0221829.
106. Dunbar DR, Moonie PA, Swingler RJ, Davidson D, Roberts R, et al. Maternally transmitted partial direct tandem duplication of mitochondrial DNA associated with diabetes mellitus. Hum Mol Genet 1993;2:1619-24.
107. Pearson HA, Lobel JS, Kocoshis SA, Niaman JL, Windmiller J, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 1979;95:976-84.
108. Rotig A, Cormier V, Blanche S, Bonnefont JP, Ledeist F, et al. Pearson’s marrow-pancreas syndrome: a multisystem mitochondrial disorder in infancy. J Clin Invest 1990;86:1601-8.
109. Grady JP, Campbell G, Ratnaike T, Blakely EL, Falkous G, et al. Disease progression in patients with single large-scale mitochondrial DNA deletions. Brain 2014;137:323-34.
110. Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histological study in one of two cases. JAMA Arch Ophthalmol 1958;60:P280-9.
111. Gallastegui J, Harlman RJ, Handler B, Lev M, Bharati S. Cardiac involvement in the Kearns-Sayre syndrome. Am J Cardiol 1987;60:385-8.
112. Hart LM, Jansen JJ, Lemkes HH, de Knijff P, Massen JA. Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decreased in leukocyte DNA upon aging. Hum Mutat 1996;7:193-7.
113. Heighton JN, Brady LI, Sadikovic B, Bulman DE, Tarnopolsky MA. Genotypes of chronic progressive external ophthalmoplegia in a large adult onset cohort. Mitochondrion 2019;49:227-31.
114. Smits BW, Fermont J, Delnooz CC, Kalkman JS, Bleijenberg G, et al. Disease impact in chronic progressive external ophthalmoplegia: more than meets the eye. Neuromuscul Disord 2011;21:272-8.
115. Yamashita S, Nishion I, Nonaka I, Goto Y. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. J Hum Genet 2008;53:598-606.
116. Piro-Megy C, Sarzi E, Tarres-Sole A, Pequignot M, Hensen F, et al. Dominant mutations in mtDNA maintenance gene
117. El-Hattab AW, Craigen WJ, Scaglia F. Mitochondrial DNA maintenance defects. Biochim et Biophys Acta- Mol Basis of Dis 2017;1863:1539-55.
118. Garrido N, Griparic L, Jokitalo E, Wartiovaara J, van der Bliek AM, et al. Composition and dynamics of human mitochondrial nucleoids. Mol Biol Cell 2003;14:1583-96.
119. Farge G, Mehmedovic M, Baclayon M, van den Wildenberg SMJL, Roos WH, et al. In vitro-reconstitution nucleoids can block mitochondrial DNA replication and transcription. Cell Reports 2014;8:66-74.
121. Lewis SC, Uchiyama LF, Nunnari J. ER-mitochondrial contacts couple mtDNA synthesis with mitochondrial division in human cells. Science 2016;353:aaf5549.
122. Ropp PA, Copeland WC. Cloning and characterization of the human mitochondrial polymerase gamma. Genomics 1996;35:449-58.
123. Young MJ, Copeland WC. Human mitochondrial DNA replication machinery and disease. Curr Opin Genet Dev 2016;38:52-62.
124. Tchikviladze M, Gilleron M, Maisonobe T, Galanaud D, Laforet P, et al. A diagnostic flow chart for POLG-related diseases based on signs sensitivity and specificity. J Neurol Neurosurg Psychiat 2015;86:646-54.
125. Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol 2013;48:167-78.
126. Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001;28:223-31.
127. Lonnqvist T, Paetau A, Valanne L, Pihko H. Recessive twinkle mutations cause severe epileptic encephalopathy. Brain 2009;132:1553-62.
128. Nikali K, Suomalainen A, Sahariren J, Kuokkanen M, Spelbrink JN, et al. Infantile onset spinocerebellar ataxia is caused by recessive mutation in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet 2005;14:2981-90.
129. Del Dotto V, Ullah F, Di Meo I, Magini P, Gusic M, et al. SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder. J Clin Invest 2020;130:108-25.
130. Kornblum C, Nicholls T, Haack TB, Scholer S, Peeva V, et al. Loss-of-function in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet 2013;45:214-9.
131. Reyes A, Melchionda L, Nasca A, Carrara F, Lamantea E, et al. RNASEH1 mutations impair mtDNA replication and cause adult-onset mitochondrial encephalomyopathy. Am J Hum Genet 2015;97:186-93.
132. Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes-many genes, common mechanisms. Neuromuscular Dis 2010;20:429-37.
133. Goltz A, Isohanni P, Pihko H, Paetau A, Paetau A, et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 2008;131:2841-50.
134. Tyynismaa H, Sun R, Ahola-Erkkila S, Almusa H, Poyhonen R, et al. Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet 2012;21:66-75.
135. Mandel H, Szargel R, Labay V, Elpelg O, Saada A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001;29:337-41.
136. Dimmock DP, Zhang Q, Dionisi-Vici C. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Hum Mut 2008;29:330-1.
137. Ronchi D, Garone C, Bordoini A, Gutierrez Rios P, Calvo SE, et al. Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. Brain 2012;135:3404-15.
138. Carrozzo R, Verrigni D, Rasmussen M, de Coo R, Amartino H, et al. Succinate-CoA ligase deficiency due to mutations in SUCLAA2 and SUCLG1: phenotype and genotype correlations in 71 patients. J Inherit Metab Dis 2016;39:243-52.
139. Besse A, Wu P, Bruni F, Donti T, Graham BH, et al. The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism. Cell Metab 2015;21:417-27.
140. Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, et al. The deoxynucleoside triphosphate triphosphohydrolase activity of SAMDH1 protein contributes to the mitochondrial DNA depletion associated with genetic deficiency of deoxyguanosine kinase. Proc Natl Acad Sci USA 2013;110:14272-7.
141. Bornstein B, Area E, Flanigan KM, Ganesh J, Jayakar P, et al. Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. Neuromuscul Dis 2008;18:453-9.
142. Bourdon A, Minai L, Derre V, Jais JP, Sarzi E, et al. Mutation of RRM2B encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nature Genet 2007;39:776-80.
143. Fratter C, Ramen P., Alston CL, Blakley EL, Craig K, et al. RRM2B mutations ae frequent in familial PEO with multiple mtDNA deletions. Neurology 2011;76:232-4.
144. Pontarin G, Fijolek A, Pizzo P, Ferraro P, Rampazzo C, et al. Ribonucleotide reduction is a cytosolic process in mammalian cell independently of DNA damage. Proc Natl Acad Sci USA 2008;105:17801-5.
145. Nishigaki Y, Marti R, Copeland WC, Hirano M. Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 2003;111:1913-21.
146. Giordano C, Sebastiani M, De Giorgio R, Travaglini C, Tancredi A, et al. Gastrointestinal dysmotility in mitochondrial neruogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 2008;173:1120-8.
147. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011;134:3326-32.
148. Farge G, Laurens N, Broekmans OD, van den Wildenberg SM, Dekker LCM, et al. Protein sliding and DNA denaturation are essential for DNA organization by human mitochondrial transcription factor A. Nat Commun 2012;3:1013.
149. Posse V, Hoberg E, Dierclx A, Shahzad S, Koolmeister C, et al. The amino terminal extension of mammalian mitochondrial RNA polymerase ensures promoter specific transcription initiation. Nucleic Acids Res 2014;42:3638-47.
150. Sologub M, Litonin D, Anikin M, Mustaev A, Temiakov D. TFB2 is a transient component of the catalytic site of the human mitochondrial RNA polymerase. Cell 2009;139:934-44.
151. Minczuk M, He J, Duch AM, Ettema TJ, Chlebowski A, et al. TEFM (c17orf42) is necessary for transcription of human mtDNA. Nucleic Acids Res 2011;39:4284-99.
152. Terzioglu MTERF1 binds mtDNA to prevent transcriptional interference at the light-strand promoter but is dispensable for rRNA gene transcription regulation. Cell Metab 2013;17:618-26.
153. D’Souza AR, Minczuk M. Mitochondrial transcription and translation: overview. Essays Biochem 2018;62:309-20.
154. Suzuki T, Nagao T, Suzuki T. Human mitochondrial diseases caused by lack of taurine modification in mitochondrial tRNAs. WIREs RNA 2011;2:376-86.
155. Suzuki T, Nagao A, Suzuki T. Human mitochondrial tRNAs: biogenesis, function, structural aspects, and disease. Annu Rev Genet 2011;45:299-329.
156. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651-3.
157. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015;116:4-12.
158. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Paviakis SG, et al. MELAS: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992;2:125-35.
159. Amunts A, Brown A, Toots J, Scheres SH, Ribosome RV. The structure of the human mitochondrial mitoribosome. Science 2015;348:95-8.
160. Brown A, Amunts A, Bai XC, Sugimoto Y, Edwards PC, et al. Structure of the large ribosomal subunit from human mitochondria. Science 2014;346:718-22.
161. Mai N, Chrzanowska-Lightowlers ZM, Lightowlers RN. The process of mammalian mitochondrial protein synthesis. Cell and Tissue Res 2017;367:5-20.
162. Ott M, Amunts A, Brown A. Organization and regulation of mitochondrial protein synthesis. Ann Rev Biochem 2016;85:77-101.
163. Lake MK, Webb BD, Stroud DA, Richman TR, Rizzenente B, et al. Biallelic mutations in MRPS34 lead to instability of the small mitochondrial subunit and Leigh syndrome. Am J Hum Genet 2017;101:239-54.
164. Chen A, Tiosano D, Guran T, Baris HN, Bayram Y, et al. Mutations in the mitochondrial ribosomal protein MRPS22 lead to primary ovarian insufficiency. Hum Mol Genet 2018;27:1913-26.
165. Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000;9:1787-96.
166. Zhou M, Xue L, Chen Y, Li H, He Q, et al. A hypertension-association mitochondrial DNA mutation introduces an m1 G37 modification into tRNAMet, altering its structure and function. J Biol Chem 2018;293:1425-38.
168. Metodiev MD, Thompson K, Alston CL, Morris AAM, He L, et al. Recessive mutations in TRMT10C cause defects in mitochondrial processing and multiple respiratory chain defects. Am J Hum Genet 2016;98:993-1000.
169. Falk MJ, Gai X, Shigematsu M, Vilardo E, Takase R, et al. A novel HSD17B10 mutation impairing the activities of mitochondrial RNase P complex causes X-linked intractable epilepsy and neurodevelopmental regression. RNA Biol 2016;13:477-85.
170. Haack TB, Kopajtich R, Freisinger P, Wieland T, Robach J, et al. ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy. Am J Hum Genet 2013;93:211-23.
171. Paucar M, Pajak A, Freyer C, Bergendal A, Dory M, et al. Chorea, psychosis, acanthocytosis and prolonged survival associated with
172. Matilainen S, Carroll CJ, Richter U, Euro L, Pohjanpelto M, et al. Defective mitochondrial RNA processing due to PNPT1 variants causes Leigh syndrome. Hum Mol Genet 2017;26:3352-61.
173. Crosby AH, Patel H, Chioza BA, Proukakis C, Gurtz K, et al. Defective mitochondrial mRNA maturation is associated with spastic ataxia. Am J Hum Genet 2010;87:655-60.
174. Van Eyck L, Bruni F, Ronan A, Briggs TA, Roscioli T, et al. Biallelic mutation in MTPAP associated with lethal encephalopathy. Neuropediatrics 2020;51:178-84.
175. Sasarman F, Brunel-Guitton C, Anatonicka H, Wai T, Shoubridge EA. LRPPRC and SLIRP interact in a ribonucleoprotein complex that regulates posttranscriptional gene expression in mitochondria. Mol Biol Cell 2010;21:1315-23.
176. Morin C, Mitchell G, Larochelle J, Lambert M, Ogier H, et al. Clinical, metabolic, and genetic aspects of cytochrome c oxidase deficiency in Saguenay-Lac-Saint-Jean. Am J Hum Genet 1993;53:488-96.
177. Ghezzi D, Saada A, D’Aamo P, Fernandez-Vizarra F, Gasparini P, et al. FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy associated with cytochrome C oxidase deficiency. Am J Hum Genet 2008;83:415-23.
178. Popow J, Alleaume AM, Curk T, Schwarzl T, Sauer S, et al. FASTKD2 is an RNA-binding protein required for mitochondrial RNA processing and translation. RNA 2015;21:1873-84.
179. Garone C, D’Souza AR, Dallabona C, Lodi T, Rebelo-Guiomar P, et al. Defect mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome. Hum Mol Genet 2017;26:4257-66.
180. Vilardo E, Nachbagauer C, Buzet A, Taschner A, Holzmann J, et al. A subcomplex of human mitochondrial RNase P is a bifunctional methyltransferase-extenisve moonlighting in mitochondrial tRNA biogenesis. Nucleic Acids Res 2012;40:11583-93.
181. Powell CA, Kopajtich R, D’Souza AR, Rorbach J, Kremer LS, et al. TRMT5 mutations cause a defect in post-translational modification of mitochondrial tRNA associated with multiple respiratory-chain deficiencies. Am J Hum Genet 2015;97:319-28.
182. Meseguer S, Boix O, Navarro-Ganzalez C, Villarroya M, Moutoual R, et al. MicroRNA-mediated differential expression of TRMU, GTPBP3 and MTO1 in cell models of mitochondrial-DNA diseases. Sci Rep 2017;7:6209.
183. Boczonadi V, Bansagi B, Horvath R. Reversible infantile mitochondrial diseases. J Inherit Metab Dis 2015;38:427-35.
185. Nagao A, Suzuki T, Katoh T, Sakaguchi Y, Suzuki T. Biogenesis of glutaminyl-mt tRNAGln in human mitochondria. Proc Natl Acad Sci USA 2009;106:16209-14.
186. Friederich MW, Timal S, Powell CA, Dallabona C, Kurolap A, et al. Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder. Nat Commun 2018;9:4065.
187. Haag S, Sloan KE, Ranjan N, Warda A, Kretschmer J, et al. NSUN3 and ABH1 modify the wobble position of mt-tRNAMet to expand codon recognition in mitochondrial translation. EMBO J 2016;35:2104-19.
188. Christain B, Haque E, Spremulli L. Ribosome shifting or splitting: it is all up to the EF-G. Mol Cell 2009;35:400-2.
189. Ravn K, Schonewolf-Greulich B, Hansen RM, Bohr AH, Duno M, et al. Neonatal mitochondrial hepatoencephalopathy caused by novel GFM1 mutations. Mol Genet Metab Rep 2015;3:5-10.
190. Valente L, Tiranti RM, Marsano E, Malfatti E, Fernandez-Vizarra C, et al. Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutation of mitochondrial elongation factors EPG1 and EFTu. Am J Hum Genet 2007;80:44-58.
191. Tsuboi M, Morita H, Nozaki Y, Akama K, Ueda T, et al. EF-G2mt is an exclusive recycling factor in mammalian mitochondrial protein synthesis. Mol Cell 2009;35:502-10.
192. Wesolowska M, Gorman GS, Alston C, Pajak A, Pyle A, et al. Adult onset Leigh syndrome in the intensive care setting: a novel presentation of a C12orf65 related mitochondrial disease. J Neuromuscul Dis 2015 2015;2:409-19.
193. Richman TR, Spahr H, Ermer JA, Davies SMK, Viola HM, et al. Loss of the RNA-binding protein TACO1 causes late-onset mitochondrial dysfunction in mice. Nat Commun 2016;7:11884.
194. Pfanner N, Warscheid B, Wiedemann N. Mitochondrial protein organization: from biogenesis to networks and function. Nat Rev Mol Cell Biol 2019;20:267-84.
195. Kang Y, Stroud DA, Baker MJ, De Souza DP, Frazier AE, et al. Sengers syndrome-associated mitochondrial acylglycerol kinase is a subunit of the human TIM22 protein import complex. Mol Cell 2017;67:457-70.
196. Reyes A, Melchionda L, Burlina A, Robinson AJ, Ghezzi D, et al. Mutations in
197. Beverly KN, Sawaya MR, Schmid E, Koehler CM. The Tim8-13 complex has multiple substrate binding sites and binds cooperatively to Tim23. J Mol Biol 2008;382:1144-56.
198. Neighbor A, Moss T, Holloway L, Yu SH, Annese F, et al. Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome. Mol Genet Genomic Med 2020;8:e1121.
199. Sevrioukova IF. Structure/function relations in AIFM1 variants associated with neurodegenerative disorders. J Mol Biol 2016;428:3650-65.
200. Sinha D, Srivastava S, D’Silva P. Functional diversity of human mitochondrial J-proteins is independent f their association with the inner membrane presequence translocase. J Biol Chem 2016;291:17345-59.
201. Richter-Dennerlein R, Korwitz A, Haag M, Tatsuta T, Dargazanli S, et al. DNAJC19, a mitochondrial chaperone associated with cardiomyopathy, forms a complex with prohibitins to regulate cardiolipin remodeling. Cell Metab 2014;20:158-71.
202. Di Fonzo A, Ronchi D, Lodi T. The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. Am J Hum Genet 2009;84:594-604.
203. Eldomery MK, Akdemir AC, Vogtle FN, Chamg WL, Mulica P, et al. MIPEP recessive syndrome of left ventricular non-compaction, hypotonia and infantile death. Genome Med 2016;8:106.
204. Jobling RK, Assoum M, Gakh O, Blaser S, Raiman JA, et al. PMPCA mutations cause abnormal mitochondrial protein processing in patients with non-progressive cerebellar ataxia. Brain 2015;138:1505-17.
205. Quiros PM, Langer T, Lopez-Otin C. New roles for mitochondrial proteases in health, ageing and disease. Nat Rev Mol Cell Biol 2015;16:345-59.
206. Baker PR II, Friederich MW, Swanson MA, Shaikh T, Bhattacharya K, et al. Variant non-ketotic hyperglycinemia is caused by mutations in
207. Kure S, Tada K, Narisawa K. Nonketotic hyperglycinemia: biochemical, molecular, and neurological aspects. Jpn J Hum Genet 1997;42:13-22.
208. Swanson MA, Coughlin CR, Scharer GH, Szerlong HJ, Bjoraker KJ, et al. Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia. Ann Neurol 2015;78:606-18.
209. Twig G, Elorza A, Molina A, Mohamed H, Wikstrom J, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008;27:433-46.
210. Shi G, McQuibban GA. The mitochondrial rhomboid protease PARL is regulated by PDK2 to integrate mitochondrial quality control and metabolism. Cell Reports 2017;18:1458-72.
212. Singh R, Jamdar SN, Goyal VD, Kumar A, Ghosh B, et al. Structure of the human aminopeptidase XPNPEP3 and comparison of its in vitro activity with Icp55 orthologs: insights into diverse cellular processes. J Biol Chem 2017;292:10035-47.
213. O’Toole JF, Liu Y, Davis EE, Westlake J, Attanasio M, et al. Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy. J Clin Invest 2010;120:791-802.
214. Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear - encoded mitochondrial metalloprotease. Cell 1998;93:973-83.
215. Pfeffer G, Gorman GS, Griffin H, Kurzawa-Akanbi M, Blakely EL, et al. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain 2014;137:1323-36.
216. Vogtle F-N, Brandl B, Larson A, Pendziwat M, Friederich MW, et al. Mutations in PMPCB encoding the catalytic subunit of the mitochondrial presequence protease cause neurodegeneration in early childhood. Am J Hum Genet 2018;102:557-73.
217. Peter B, Waddington CL, Olahova M, Sommerville EW, Hopton S, et al. Defective mitochondrial protease LonP1 can cause classical mitochondrial disease. Hum Mol Genet 2018;27:1743-53.
218. Strauss KA, Jinks RN, Puffenberger EG, Venkatesch S, Singh K, et al. CODAS syndrome is associated with mutations of LONP1, encoding mitochondrial AAA+ Lon Protease. Am J Hum Genet 2015;96:121-35.
219. Bertelsen B, Melchior L, Jensen LR, Groth C, Glenthoj B, et al. Intragenic deletions affective two alterative transcripts of the IMMP2L gene in patients with Tourette syndrome. Eur J Hum Genet 2014;22:1283-9.
220. Unal Gulsuner H, Gulsuner S, Mercan FN, Onat OE, Walsh T, et al. Mitochondrial serine protease HTRA2 p.G199S in a kindred with essential tremor and Parkinson disease. Proc Natl Acad Sci USA 2014;111:18285-90.
221. Olahova M, Thompson K, Hardy SA, Barbosa IA, Besse A, et al. Pathological variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. J Inherit Metab Dis 2017;40:121-30.
222. Jenkinson EM, Rehman AU, Walsh T, Clayton-Smith J, Lee K, et al. Perrault syndrome is caused by recessive mutation in CLPP, encoding a mitochondrial ATP-dependent chambered protease. Am J Hum Genet 2013;92:605-13.
223. Cesnekova J, Rodinova M, Hansikova H, Zeman J, Stiburek L. Loss of mitochondrial AAA proteases AFG3L2 and YME1L impairs mitochondrial structure and respiratory chain biogenesis. Int J Mol Sci 2018;19:3930.
224. Anand R, Wai T, Baker JM, Kladt N, Schauss AC, et al. The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. J Cell Biol 2014;204:919-29.
225. Patron M, Sprenger HG, Langer T. m-AAA proteases, mitochondrial calcium homeostasis and neurodegeneration. Cell Res 2018;28:296-306.
226. Gilquin B, Taillebourg E, Cherradi N, Hubstenberger A, Gay O, et al. The AAA+ ATPase ATAD3A controls mitochondrial dynamics at the interface of the inner and outer membranes. Mol Cell Biol 2010;30:1984-96.
227. Cooper HM, Yang Y, Ylikallio E, Khairullin R, Woldegebriel R, et al. ATPase-deficient mitochondrial inner membrane protein ATAD3A disturbs mitochondrial dynamics in dominant hereditary spastic paraplegia. Hum Mol Genet 2017;26:1432-43.
228. Harel T, Hee Yoon W, Garone C, Gu S, Coban-Akdemir Z, et al. Recurrent de novo and biallelic variation of ATAD3A, encoding a mitochondrial membrane protein, results in distinct neurological syndromes. Am J Hum Genet 2016;99:831-45.
229. Rouault TA, Maio N. Biogenesis and functions of mammalian iron-sulfur proteins in the regulation of iron homeostasis and pivotal metabolic pathways. J Biol Chem 2017;292:12744-53.
230. Braymer JJ, Lill R. Iron sulfur cluster biogenesis and trafficking in mitochondria. J Biol Chem 2017;292:12754-63.
231. Rouault TA. The indispensable role of mammalian iron sulfur proteins in function and regulation of multiple diverse metabolic pathways. Biometals 2019;32:343-53.
232. Costain G, Ghosh MC, Maio N, Carnevale A, Si YC, et al. Absence of iron-responsive element-binding protein 2 causes a novel neurodegenerative syndrome. Brain 2019;42:1195-202.
233. Shi Y, Ghosh M, Kovtunovych G, Crooks DR, Rouault TA. Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis. Biochim Biophys Acta 2012;1823:484-92.
234. Peng Y, Shinde DN, Valencia CA, Mo JS, Rosenfeld J, et al. Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Hum Mol Genet 2017;26:4937-50.
235. Paul A, Drecourt A, Petit F, Deguine DD, Vasnier C, et al. FDXR mutation cause sensorial neuropathies and expand the spectrum of mitochondrial Fe-S-synthesis diseases. Am J Hum Genet 2017;101:630-7.
236. Gurgel-Giannetti J, Lynch DS, Brandao de Paiva AR, Lucato LT, Yamamoto G, et al. A novel complex neurological phenotype due to a homozygous mutation in FDX1. Brain 2018;141:2289-98.
237. Farhan SMK, Wang J, Robinson JF, Lahiry P, Sui VM, et al. Exome sequencing identifies NFS1 deficiency in a novel Fe-S cluster disease, infantile mitochondrial complex II/III deficiency. Mol Genet Genomic Med 2014;2:73-80.
238. Lim SC, Friemel M, Marum JE, Tucker EJ, Bruno D, et al. Mutations in LYMR4, encoding iron-sulfur cluster biogenesis factory ISD11, cause deficiency of multiple respiratory chain complexes. Hum Mol Genet 2013;22:4460-73.
239. Mochel F, Knight MA, Tong WH, Hernandex D, Ayyad K, et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet 2008;82:652-60.
240. Koeppen AH. Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011;303:1-12.
241. Torraco A, Stehling O, Stumpfig C, Rosser R, De Rasmo D, et al. ISCA1 mutation in a patient with infantile-onset leukodystrophy caused defects in mitochondrial [4Fe-4S] proteins. Hum Mol Genet 2018;27:2739-54.
242. Kumar V, Kumar AA, Sanawar R, Jaleel A, Kumar TRS, et al. Membrane transporter ABCB7 which contributes to iron overload, mitochondrial dysfunction, metabolic shift and worsens cardiac function. Sci Rep 2019;9:1370.
243. Kruer MC, Hiken A, Gregory A, Malandrini A, Clark P, et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011;134:947-58.
244. Hogarth P, Gregory A, Kruer MC, Wagoner W, Natowicz MR, et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013;80:268-75.
245. Gregory A, Lotia M, Joeng SY, Fox R, Zhen D, et al. Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). Mol Genet Genomic Med 2019;7:e00736.
246. Dusi S, Valletta L, Haack TB, Tsuchiya Y, Venco P, et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet 2014;94:11-22.
247. Almannai M, Alsamri, Alqasmi A, Faqeih E, Mutairi F, et al. Expanding the phenotype of SLC24A42-associated mitochondrial encephalopmyopathy. Clin Genet 2018;93:1097-102.
248. Ma Z, Turk J. The molecular biology of the group VIA CA2+-independent phospholipase A2. Prog Nucleic Acid Res Mol Biol 2001;67:1-33.
249. Kinghorn KJ, Castillo-Quan JI, Bartolome F, Angelova PR, Li L, et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 2015;138:1801-16.
250. Tello C, Darling A, Lupo V, Perez-Duenas B, Espinos C. On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation. Clin Genet 2018;93:731-40.
251. Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid synthesis defects. J Inherit Metab Dis 2014;37:553-63.
252. Paul BT, Tesfay L, Winkler CR, Torti FM, Torti SV. Sideroflexin 4 affect Fe-S cluster biogenesis, iron metabolism, mitochondrial respiration and heme biosynthesis enzymes. Sci Rep 2019;9:19634.
253. Hildick-Smith GJ, Cooney JD, Garone C, Kremer LS, Haack TB, et al. Macrocytic anemia and mitochondriopathy resulting for a defect in sideroflexin 4. Am J Hum Genet 2013;93:906-14.
254. Giacomelli M, Pyakurel A, Clytsou C, Scorrano L. The cell biology of mitochondrial membrane dynamics. Nature Reviews/Mol Cell Biol 2020;21:204-24.
255. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nature Rev Mol Cell Biol 2007;8:870-9.
256. Waterham HR, Koster J, van Roermund CWT, Mooyer PAW, Wanders RJA, et al. A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med 2007;356:1736-41.
257. Schmid SJ, Wagner M, Goetz C, Makowski C, Freisinger P, et al. A de novo dominant negative mutation in DMN1L causes sudden onset status epilepticus with subsequent epileptic encephalopathy. Neuropediatrics 2019;50:197-201.
258. Nasca A, Nardecchia F, Commone A, Semeraro M, Legati A, et al. Clinical and biochemical features in a patient with mitochondrial fission factor gene alteration. Front Genet 2018;9:625.
259. Niemann A, Wagner KM, Ruegg M, Suter U. GDPA1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. Neurobiol Dis 2009;36:509520.
261. Renaldo F, Amati-Bonneau P, Slama A, Romana C, Forin V, et al. MFN2, a new gene responsible for mitochondrial DNA depletion. Brain 2012;135:e223.
262. Del Dotto V, Fogazza M, Carelli V, Rugolo M, Zanna C. Eight human OPA1 isoforms, long and short: what are they for? BBA Bioenergetics 2018;1859:263-9.
263. Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy “plus” phenotypes. Brain 2008;131:338-51.
264. Kimura M, Okano Y. Human Misato regulates mitochondrial distribution and morphology. Exp Cell Res 2007;313:1393-404.
265. Gal A, Balicza P, Weaver D, Naghdl S, Joseph SK, et al. MSTO1 is a cytoplasmic pro-mitochondrial fusion protein, whose mutation induces myopathy and ataxia in humans. EMBO Mol Med 2017;9:967-84.
266. Nasca A, Scotton C, Zaharieva I, Neri M, Selvatici R, et al. Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia. Hum Mutat 2017;38:970-7.
267. Girard M, Lariviere R, Parfitt DA, Deane EC, Gaudet R, et al. Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Sagnuenay (ARSACS). Proc Natl Acad Sci 2012;109:1661-6.
268. Lee CA, Chin LS, Li L. Hypertonia-linked protein Trak1 functions with mitofusions to promote mitochondrial tethering and fusion. Protein Cell 2018;9:693-716.
269. Barel O, Malicdan MCV, Ben-Zeev B, Kandel J, Pri-Chen H, et al. Deleterious variants in TRAK1 disrupt mitochondrial movement and cause fatal encephalopathy. Brain 2017;140:568-81.
270. Sagie S, Lerman-Sagie T, Maljevic S, Yosovich K, Detert K, et al. Expanding the phenotype of TRAK1 mutations: hyperplexia and refractory status epilepticus. Brain 2018;141:e55.
271. Janer A, Prudent J, Paupe V, Fahiminya S, Majewski J, et al. SLC26A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med 2016;8:1019-38.
272. Abrams AJ, Hufnagel RB, Rebelo A, Zanna C, Patel N, et al. Mutations I SLC26A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat Genet 2015;47:926-32.
273. Abrams AJ, Fontanes F, Tan NBL, Buglo E, Campeanu IJ, et al. Insights into the genotype-phenotype correlation and molecular function of SLC24A46. Hum Mut 2018;39:1995-2007.
274. Goswami R, Majumdar T, Dhar J, Chattopadhyay S, Bandyopadhyay SK, et al. Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res 2013;23:1025-42.
275. Shahni R, Cale CM, Anderson G, Osellame LD, Hambleton S, et al. Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. Brain 2015;138:2834-46.
276. Anding AL, Wang C, Chang TK, Sliter DA, Powers CM, et al. VPS13D encodes a ubiquitin-binding protein that is required for the regulation of mitochondrial size and clearance. Curr Biol 2018;28:287-95.
277. Soeng E, Insolera R, Dulovic M, Kamsteeg EJ, Trinh J, et al. Mutations in VPS13D lead to a new recessive ataxia with spasticity and mitochondrial defects. Ann Neurol 2018;83:1075-88.
278. Kumar N, Leonzino M, Hancock-Cerutti W, Horenkamp FA, Li Q, et al. VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. J Cell Biol 2018;217:3625-39.
279. Gai X, Ghezzi D, Johnson MA, Biagosch CA, Shamseldin HE, et al. Mutations in
280. Sabouny R, Wong R, Lee-Glover L, Greenway SC, Sinasac DS, et al. Characterization of the C584R variant in the mtDNA depletion syndrome gene FBXL4, reveals a novel role for FBXL4 as a regulator of mitochondrial fusion. Biochim Biophys Acta Mol Basis of Dis 2019;1865:165536.
281. Huemer M, Darall D, Schossig A, Abdenur JE, Al Jasmi F, et al. Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to
282. Mandel H, Saita S, Edvardson S, Jalas C, Shaag A, et al. Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria. J Med Genet 2016;53:690-6.
283. Horga A, Bugiardine E, Manole A, Bremner F, Jaunmuktane Z, et al. Autosomal dominant optic neuropathy and cataract “plus” phenotype including axonal neuropathy. Neurol Genet 2019;5:e322.
284. Costeff H, Gadoth N, Apter N, Prialnic M, Savir H. A familial syndrome of infantile optic atrophy, movement disorder, and spastic paraplegia. Neurology 1989;39:595-7.
285. Gaier ED, Sahai I, Wiggs JL, McGeeney B, Hoffman J, et al. Novel homozygous OPA3 mutation in an Afghani family with 3-methyglutaconic aciduria type III and optic atrophy. Ophthalmic Genet 2019;40:570-3.
286. Nazli A, Safdar A, Saleem A, Akhtar M, Brady LI, et al. A mutation in the TMEM65 gene results in mitochondrial myopathy with severe neurological manifestations. Eur J Hum Genet 2017;25:744-51.
287. Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B, et al. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun 2000;279:378-82.
288. Clarke SLN, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, et al. Barth syndrome. Orph J Rare Dis 2013;8:23.
289. Nishino I. New congenital muscular dystrophy due to CHKB mutations. Rinsho Shinkeigaku 2013;53:1112-3.
290. Marchet S, Invernizzi F, Blasevich F, Bruno V, Dusi S, et al. Alteration of mitochondrial membrane inner potential in three Italian patients with megaconial congenital muscular dystrophy carrying new mutations in CHKB gene. Mitochondrion 2019;47:24-9.
291. Wortmann SB, Vaz FM, Gardeitchik T. Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial functions and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 2012;44:797-802.
292. Mancuso DJ, Sims HF, Han X, Jenkins CM, Guan SP, et al. Genetic ablation of calcium-independent phospholipase A2 gamma leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetics phenotype. J Biol Chem 2007;282:34611-22.
293. Shukla A, Saneto RP, Hebbar M, Mirzaa G, Girisha KM. A neurodegerative mitochondrial disease phenotype due to biallelic loss-of-function variants in PNPLA8 encoding calcium-independent phospholipase A2γ. Am J Med Genet 2018;176A:1232-7.
294. Yagi M, Uchiumi T, Takazaki S, Okuno B, Nomura M, et al. p.32/gC1qR is indispensable for fetal development and mitochondrial translation: importance of its RNA-binding ability. Nucleic Acids Res 2012;40:9717-37.
295. Feichtinger RG, Olahova M, Kishita Y, Garone C, Kremer LS, et al. Biallelic C1QBP mutations cause severe neonatal-childhood-, or later-onset cardiomyopathy associated with combined respiratory-chain deficiencies. Am J Hum Genet 2017;101:525-38.
296. Angebault C, Guichet P-O, Talmat-Amar Y, Charif M, Gerber S, et al. Recessive mutations in RTN4IP1 cause isolated and syndromic optic neuropathies. Am J Hum Genet 2015;97:754-60.
297. Palmieri F, Scarcia P, Monne M. Diseases caused by mutations in mitochondrial carrier genes SLC25: a review. Biomolecules 2020;10:655.
298. Ortigoza-Escobar JD, Alfadhel M, Molero-Luis M, Darin N, Spiegel R, et al. Thiamine deficiency in childhood with attention to genetic causes: survival and outcome predictors. Ann Neurol 2017;82:317-30.
299. Marce-Grau A, Marti-Sanchez L, Baide-Mairena H, Ortigoza-Escobar JD, Perez-Duenas B. Genetic defects of thiamine transport and metabolism: a review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis 2019;42:581-97.
300. Bottega R, Perrone MD, Vecchiato K, Taddio A, Sabui S, et al. Functional analysis of the third identified SLC25A19 mutation causative for thiamine metabolism dysfunction syndrome 4. J Hum Genet 2019;64:1075-81.
301. Maid H, King MS, Smith AC, Kunji ERS. Pathogenic mutations of the human mitochondrial citrate carrier SLC25A1 impaired citrate export required for lipid, dolichol, ubiquinone and sterol synthesis. Biochim Biophys Acta Bioenerg 2018;1859:1-7.
302. Boulet A, Vest KE, Maynard MK, Gammon MG, Russell AC, et al. The mammalian phosphate carrier SLC25A3 is a mitochondrial copper transporter required for cytochrome c oxidase biogenesis. J Biol Chem 2018;293:1887-96.
303. Mayr JA, Zimmermann FA, Horvath R, Schneider HC, Schoser B, et al. Deficiency of the mitochondrial phosphate carrier presenting as myopathy and cardiomyopathy in a family with three affected children. Neuromuscul Disord 2011;21:803-8.
304. von Renesse A, Morales-Gonzalez S, Gill E, Salomons GS, Stenzel W, et al. Muscle weakness, cardiomyopathy and L-2-hydroxyglutaric aciduria associated with a novel recessive
305. Thompson K, Majd H, Dallabona C, Reinson K, King MS, et al. Recurrent de novo dominant mutations in SLC25A4 cause severe early onset mitochondrial disease and loss of mitochondrial DNA copy number. Am J Hum Genet 2016;99:860-76.
306. Punzi G, Porcelli V, Ruggiu M, Hossain MF, Menga A, et al. SLC25A10 biallelic mutations in intractable epileptic encephalopathy with complex I deficiency. Hum Mol Genet 2018;27:499-504.
307. Falk MJ, Li D, Gai X, McCormick E, Place E, et al. AGC1 deficiency causes infantile epilepsy, abnormal myelination, and reduced N-acetylaspartate. JIMD Rep 2014;14:77-85.
308. Wiborm R, Lasorsa FM, Tohonen V, Barbaro M, Sterky FH, et al. AGC1 deficiency associated with global cerebral hypomyelination. New Engl J Med 2009;361:489-95.
309. Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J Hum Genet 2002;47:333-41.
310. Camacho JA, Obie C, Biery B, Goodman BK, Hu CA, et al. Hyperornithinemia-syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet 1999;22:151-8.
311. Khan S, Ansar M, Khan AK, Shah K, Muhammad N, et al. A homozygous missense mutation in SLC25A16 is associated with autosomal recessive isolated fingernail dysplasia in a Pakistani family. Br J Dermatol 2018;178:556-8.
312. Lopriore E, Gemke RJ, Verhoeven NM, Jakobs C, Wanders RJ, et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 2001;160:101-4.
313. Iacobazzi V, Invernizzi F, Baratta S, Pons R, Chung W, et al. Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat 2004;24:312-20.
314. Boczonadi V, King MS, Smith AC, Olahova M, Bansagi B, et al. Mitochondrial oxodicarboxylated carrier deficiency is associated with mitochondrial depletion and spinal muscular atrophy-like disease. Genet Med 2018;20:1224-35.
315. Fiermonte G, Palmieri L, Todisco S, Agrimi G, Palmieri F, et al. Identification of the mitochondrial glutamate transporter. Bacterial expression, reconstitution, functional characterization and tissue distribution of two human isoforms. J Biol Chem 2002;277:19289-94.
316. Molinari F, Raas-Rothschild A, Rio M, Fiermonte G, Encha-Razavi F, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet 2005;76:334-9.
317. Cohen R, Basel-Vanagaite L, Goldberg-Stern H, Halevy A, Shuper A, et al. Two siblings with early infantile myoclonic encephalopathy due to mutation in the gene encoding mitochondrial glutamate/H+ symporter SLC25A22. Eur J Paediatr Neurol 2014;18:801-5.
318. Fiermonte G, De Leonardis F, Todisco S, Palmieri L, Lasorsa RM, et al. Identification of the mitochondrial ATP-Mg/Pi transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms. J Biol Chem 2004;279:30722-30.
319. Writzl K, Maver A, Kovacic L, Martinex-Valero P, Contreras L, et al. De novo mutations in SLC25A24 cause a disorder characterized by early aging, bone dysplasia, characteristic face, and early demise. Am J Hum Genet 2017;101:844-55.
320. Kishita Y, Pajak A, Bolar NA, Marobbio CMT, Maffezzini C, et al. Intra-mitochondrial methylation deficiency due to mutations in SLC25A26. Am J Hum Genet 2015;97:761-8.
321. Spaan AN, Ijlst L, van Roermund CW, Wijburg FA, Wanders RJ, et al. Identification of the human FAD transporter and its potential role in multiple acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2005;86:441-7.
322. Hellebrekers DMEI, Sallevelt SCEH, Theunissen TEJ, Hendricks ATM, Gottschalk RW, et al. Novel SLCA2532 mutation in a patient with a severe neuromuscular phenotype. Eur J Hum Genet 2017;25:886-8.
323. Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nature Genet 2009;42:651-3.
324. Wan J, Steffen J, Yourshaw M, Mamsa H, Andersen E, et al. Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain 2016;139:2877-90.
325. Abrams AJ, Fontanesi F, Tan NBL, Buglo E, Campeanu IJ, et al. Insights into the genotype-phenotype correlation and molecular function of LSC25A46. Hum Mutat 2018;39:1995-2007.
326. Sancak Y, Markhard AL, Kitami T, Kovacs-Bodgan E, Kamer KJ, et al. EMRE is an essential component of the mitochondrial calcium uniporter complex. Science 2013;342:1379-82.
327. Kamer KJ, Grabarek Z, Mootha VK. High-affinity cooperative Ca2+ binding by MICU1-MICU2 serves as an on-off switch for the uniporter. EMBO Reports 2017;18:1397-411.
328. Musa S, Eyaid W, Kamer K, Ali R, Al-Mureikhi M, et al. A middle eastern founder mutation expands the genotypic and phenotypic spectrum of mitochondrial MICU1 deficiency: a report of 13 patients. J Inherit Metab Dis 2019;43:79-83.
329. Shamseldin HE, Alasmari A, Salih MA, Samman MM, Mian SA, et al. A null mutation in MICU2 causes abnormal mitochondrial calcium homeostasis and a severe neurodevelopmental disorder. Brain 2017;140:2806-13.
330. Choi EK, Nguyen TT, Gupta N, Iwse S, Seo YA. Functional analysis of SLC39A8 mutations and their implications for manganese deficiency and mitochondrial disorders. Sci Rep 2018;83:3163.
331. Herzig S, Raemy E, Montessauit S, Veuthey JL, Zamboni N, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012;337:93-6.
332. Oonthonpan L, Rauckhorst AM, Gray LR, Boutron AC, Taylor EB. Two human patient mitochondrial pyruvate carrier mutations reveal distinct molecular mechanisms of dysfunction. JCI Insight 2019;5:e126132.
333. Prajapati S, Haselbach D, Wittig S, Patel MS, Chari A, et al. Structural and functional analyses of the human PCH complex suggests a “Division-of-Labor” mechanism by local E1 and E3 clusters. Structure 2019;27:1124-36.
334. Patel KP, O’Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab 2012;105:34-43.
335. Perez-Stiles G, Ly C, Grant A, Drew AP, Yiu EM, et al. Pathologic mechanisms underlying X-linked Charcot-Marie-Tooth neuropathy (CMTX6) in patients with pyruvate dehydrogenase kinase 3 mutation. Neurobiol Dis 2016;94:237-44.
336. Spiegel R, Pines O, Ta-Shma A, Burak E, Shaag A, et al. Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase,
337. Fattal-Valevski A, Eliyahu H, Frenkel ND, Elmaliach G, Hausman-Kedem M, et al. Homozygous mutations, p. Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy. Neurogenetics 2017;18:57-61.
338. Hartong DT, Dange M, McGee TL, Berson El, Dryja TP, et al. Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle. Nat Genet 2008;40:1230-4.
339. Kerrigan JF, Aleck KA, Tarby TJ, Bird CR, Heidenrich RA. Fumeric aciduria: clinical and imaging features. Ann Neurol 2000;47:583-8.
340. Sudarshan S, Linehan WM, Neckers L. HIF and fumerate hydratase in renal cancer. Br J Cancer 2007;96:403-7.
341. Ait-El-Mkadem S, Dayem-Quere M, Gusic M, Chaussenot A, Bannwarth S, et al. Mutations in
342. Coutelier M, Golzet C, Durr A, Gabarou F, Morais S, et al. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain 2015;138:2191-205.
343. Shi H, Enriquez A, Rapadas M, Martin EMMA, Wang R, et al. NAD deficiency, congenital malformations, and niacin supplementation. N Eng J Med 2017;377:544-52.
344. Ohashi K, Kawai S, Murata K. Identification and characterization of a human mitochondrial NAD kinase. Nat Commun 2012;3:1248.
345. Tort F, Ugarteburu O, Torres M, Garcia-Villoria J, Giros M, et al. Lysine restriction and pyridoxal phosphate administration in a NADK2 patient. Pediatrics 2016;138:e20154534.
346. Pomerantz DJ, Ferdinandusse S, Cogan J, Cooper DN, Reimschisel T, et al. Clinical heterogeneity of mitochondrial NAD kinase deficiency caused by a NADK2 start loss variant. Am J Med Genet A 2018;176:692-8.
347. Kremer LS, Danhauser K, Herebian D, Ramadza DP, Piekutowska-Abramczuk D, et al. NAEX mutations disrupt the cellular NAD(P)HX repair system and cause a lethal neurometabolic disorder of early childhood. Am J Hum Genet 2016;99:894-902.
348. Heimer G, Keratar JM, Riley LG, Balasubramaniam S, Eyal E, et al. MECR mutations cause childhood-onset dystonia and optic atrophy, a mitochondrial fatty acid synthesis disorder. Am J Hum Genet 2016;99:1229-44.
349. Guimier A, Gordon CT, Godard F, Ravenscroft G, Oufadem M, et al. Biallelic PPA2 mutations cause sudden unexpected cardiac arrest in infancy. Am J Hum Genet 2016;99:666-73.
350. Poon CKL, Halvorsen M, Goldstein DB, Rabin R, Cecchin F, et al. Sudden unexpected death in asymptomatic infants due to
351. Kennedy H, Haack TB, Hartill V, Matakovic L, Baumgartner ER, et al. Sudden cardiac death due to deficiency of the mitochondrial inorganic pyrophosphatase PPA2. Am J Hum Genet 2016;99:674-82.
352. Sharpe AJ, McKenzie M. Mitochondrial fatty acid oxidation disorders associated with short-chain enoyl-CoA hydratase (ECHS1) deficiency. Cells 2018;7:46.
353. Peters H, Buck N, Wanders R, Ruiter J, Waterham H, et al. ECHS1 mutations in Leigh disease: a new inborn error of metabolism affecting valine metabolism. Brain 2014;137:2903-8.
354. Stiles AR, Ferdinandusse S, Besse A, Appadurai V, Leydiker KB, et al. Successful diagnosis of HIBCH deficiency from exome sequencing and positive retrospective analysis of newborn screening cards in two siblings presenting with Leigh’s syndrome. Mol Genet Metab 2015;115:161-7.
355. Barth PG, Hoffmann GF, Jaeken JJ, Lehnert W, Hanefeld F, et al. L-2-hydroxyglutaric aciduria: a novel inherited neurometabolic disease. Ann Neurol 1992;32:66-71.
356. Steenweg ME, Jakobs C, Errami A, van Dooren SJM, Adeva Bartolome MTA, et al. An overview of L-2-Hydroxyglutarate dehydrogenase gene (
357. Pop A, Struys E, Jansen EEW, Fernandez MR, Kanhai W, et al. D-2-hydroxyglutaric aciduria type I: functional analysis of
358. Lu J, Holmgren A. Thioredoxin system in cell death progression. Antioxid Redox Signal 2012;17:1738-47.
359. Holzerova E, Danhauser K, Haack TB, Dremer LS, Melcher M, et al. Human thioredoxin 2 deficiency impairs mitochondrial redox homeostasis and causes early-onset neurodegeneration. Brain 2016;139:346-54.
360. Zafeiriou DI, Augoustides-Savvopoulou P, Hass D, Smet J, Triantafyllou P, et al. Ethylmalonic encephalopathy: clinical and biochemical observations. Neuropediatrics 2007;38:78-82.
361. Grings M, Seminotti B, Karunanidhi A, Ghaloul-Gonzalez L, Mohsen AW, et al. ETHE1 and MOCS1 deficiencies: disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts. Sci Rep 2019;9:12651.
362. Parikh S, Karaa A, Goldstein A, Bertini ES, Chinnery PF, et al. Diagnosis of “possible” mitochondrial disease: an existential crisis. J Med Genet 2019;56:123-30.
363. Niyazov DM, Kahler SG, Frye FE. Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment. Mol Syndrom 2016;7:122-137.
364. Wallace DC, Chalkia D. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harb Perspect Biol 2013;5:a021220.
365. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004426.pub3/abstract. [Last accessed on 21 Sep 2020].
366. Distelmaier F, Haack TB, Wortmann SB, Mayr JA, Prokisch H. Treatable mitochondrial diseases: cofactor metabolism and beyond. Brain 2017;140:1-4.
367. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, et al. Single dose gene-replacement therapy for spinal muscular atrophy. New Engl J Med 2017;377:1713-22.
